PRIME POLICY GROUP

Lobbying for KEDRION BIOPHARMA · Production of Plasma-Derived Therapies

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · $170,000.00 income · posted Jul 22, 2025

Lobbying activity 1

Trade (domestic/foreign)

Pharmaceutical tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem